AGA/ACG · 2023

Chronic Idiopathic Constipation — Management Guideline

Source: AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation — American Journal of Gastroenterology, 2023

✓ Edition checked 3 Oct 2026 — AGA/ACG 2023 is the current edition as of this date.

View the official source ↗

Guideline: Strong Guideline: Conditional Guideline: Not recommended ClinicoQ pathway suggestion (not from the cited guideline)

Diagnosis

Diagnostic criteria Chronic idiopathic constipation is a disorder of gut-brain interaction causing infrequent and incomplete defecation without an identifiable mechanical or metabolic cause.

⚠ Alarm features (investigate before diagnosing)

Rectal bleeding or a positive fecal occult blood test
Unintended weight loss
Iron deficiency anemia
Family history of colorectal cancer or IBD
New-onset constipation after age 50
Palpable abdominal or rectal mass

Initial workup

Test	When to order
Digital rectal exam	In all patients, to assess for structural causes or an evacuation disorder.
Colonoscopy	Alarm features present, or age-appropriate colorectal cancer screening is due.
Thyroid function, calcium, glucose	To rule out metabolic causes if clinically suspected.

Treatment

First-line

1 Fiber supplementation (psyllium) Conditional (Guideline recommendation) — especially with low dietary fiber intake

Dose: Start with a small daily dose, titrate up gradually
Duration: Ongoing
Evidence level: Low-Moderate
Avoid if: Bowel obstruction; severe bloating that worsens with fiber
If no response ClinicoQ pathway: Add an osmotic laxative

2 Polyethylene glycol (PEG) Strong (Guideline recommendation)

Dose: 17 g (one capful) dissolved in water, once daily
Duration: Ongoing, reassess response
Evidence level: Moderate
Avoid if: Known or suspected bowel obstruction
If no response ClinicoQ pathway: Add a stimulant laxative as needed, or move to prescription options

If OTC options fail

1 Bisacodyl or senna (stimulant laxative) Strong for bisacodyl/sodium picosulfate (short-term use or rescue therapy); Conditional for senna (low certainty of evidence)

Dose: Bisacodyl 5–10 mg at bedtime as needed
Duration: As needed or short-term use
Evidence level: Moderate
Avoid if: Bowel obstruction
If no response ClinicoQ pathway: Move to a prescription secretagogue

2 Linaclotide Strong (Guideline recommendation)

Dose: 145 mcg once daily on an empty stomach (CIC dose — lower than the 290 mcg IBS-C dose)
Duration: Reassess at 4 weeks
Evidence level: Moderate
Avoid if: Known/suspected mechanical GI obstruction; not for patients under 6 years old
If no response ClinicoQ pathway: Try plecanatide or prucalopride

3 Prucalopride Strong (Guideline recommendation)

Dose: 2 mg once daily (1 mg for patients over 65, renal impairment, or severe hepatic impairment)
Duration: Reassess at 4 weeks
Evidence level: Moderate
Avoid if: Mechanical GI obstruction
If no response ClinicoQ pathway: Refer for specialist GI evaluation

✕ Treatments the guideline advises against

PEG as treatment for global IBS-C symptoms (ACG 2021 and AGA 2022 differ): ACG 2021 suggests against PEG for global IBS-C symptoms (it improves stool frequency but not abdominal pain), whereas AGA 2022 makes a conditional suggestion for laxatives such as PEG in IBS-C, so the two IBS guidelines differ. PEG remains appropriate for chronic idiopathic constipation as above.

⚠️ This is an educational summary of current international clinical practice guidelines and does not replace individualized clinical judgment. Final treatment decisions remain the responsibility of the treating physician.